The company's monoclonal antibody drug candidates and diagnostics products detect and target tumors without harming healthy cells, improving outcomes and extending survival for cancer patients. Precision Biologics focuses on developing innovative therapeutics and diagnostics that enable earlier detection and intervention. Their current clinical trials are directed towards late-stage solid tumors, and they utilize proprietary cancer vaccines to create groundbreaking antibody therapeutics.